Show simple item record

dc.contributor.authorMARTINEAU, AR
dc.contributor.authorjolliffe, DA
dc.contributor.authorgriffiths, CJ
dc.contributor.authorgreenberg, L
dc.contributor.authorhooper, RL
dc.contributor.authorcamargo, C
dc.contributor.authorkerley, C
dc.contributor.authorjensen, M
dc.contributor.authormauger, D
dc.contributor.authorstelmach, I
dc.contributor.authorurashima, M
dc.date.accessioned2017-10-06T09:45:04Z
dc.date.available2017-10-06T09:45:04Z
dc.date.issued2017-10-03
dc.date.submitted2017-09-04T08:40:11.541Z
dc.identifier.issn2213-2600
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/26923
dc.description.abstractBackground: Aggregate data meta-analysis of randomized controlled trials (RCTs) shows that vitamin D supplementation reduces the rate of moderate/severe asthma exacerbations, defined as those requiring treatment with systemic corticosteroids. It is not known whether this effect is restricted to patients with lower baseline vitamin D status. Methods: We conducted a systematic review with one-step and two-step meta-analyses of individual participant data (IPD) from randomised controlled trials adjusting for age, sex, and clustering by study. Sub-group analyses were done to determine whether effects of vitamin D on risk of asthma exacerbation varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, age, sex, ethnic / racial origin, body mass index, vitamin D dosing regimen, use of inhaled corticosteroids or study duration. Findings: IPD were sought for eight eligible randomised controlled trials (total 1,078 participants), and obtained for 955/978 (97.6%) participants in seven studies. Vitamin D supplementation reduced the rate of moderate/severe asthma exacerbation among all participants (adjusted Incidence Rate Ratio [aIRR] 0.74, 95% CI 0.56 to 0.97, P=0.03, 955 participants in 7 studies). Sub-group analyses revealed that statistically significant protective effects were seen in participants with baseline 25(OH)D <25 nmol/L (aIRR 0.33, 95% CI 0.11 to 0.98, P=0.046, 92 participants in 3 studies) but not in those with higher baseline 25(OH)D levels (aIRR 0.77, 95% CI 0.58 to 1.03, P=0.08, 764 participants in 6 studies; P for interaction =0.25). P values for interaction were also >0.05 for all other sub-group analyses performed. Interpretation: Vitamin D supplementation reduced the rate of moderate/severe asthma exacerbation overall. We did not find definitive evidence that effects of this intervention differed across sub-groups of patients. Funding: Health Technology Assessment Program, National Institute for Health Research (Reference Number 13/03/25)en_US
dc.description.sponsorshipHealth Technology Assessment Program, National Institute for Health Research (reference number 13/03/25).en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofLancet Respiratory Medicine
dc.rights© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleVitamin D supplementation to prevent asthma exacerbations: systematic review and meta-analysis of individual participant dataen_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.1016/S2213-2600(17)30306-5
pubs.organisational-group/Queen Mary University of London
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute/Centre for Primary Care and Public Health
pubs.publication-statusAccepted


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Return to top